Asthma is a chronic inflammatory disease that often features eosinophilia, 
especially in its most severe forms. Monoclonal antibodies directed towards 
interleukin-5, such as mepolizumab or reslizumab, were shown to be very 
effective at reducing blood and airways eosinophilia. When administered monthly 
by intravenous or subcutaneous injection in severe eosinophilic asthmatic 
patients, they reduce severe exacerbation rate by 50 %, improve asthma control 
and quality of life, and have an oral glucocorticoids sparing effect in those 
requiring oral corticoids as maintenance therapy.